AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter...

Related Keywords

Canada ,United States ,Canadian ,Vince Angotti ,Department Of Defense ,Company Annual Report On Form ,Drug Administration ,Exchange Commission ,Prnewswire Acelrx Pharmaceuticals Inc ,Nasdaq ,Nasdaq Stock Market ,Acelrx Pharmaceuticals Inc ,Investigational Device Exemption ,Opinion Leader ,Chief Executive Officer ,Nafamostat Efficacy ,Premarket Approval ,Key Opinion Leader ,Institutional Review Board ,Recent Corporate ,United States Food ,Nantahala Capital Management ,Standard Time ,Upcoming Events ,Breakthrough Device Designation Status ,Acelrx Pharmaceuticals ,Private Securities Litigation Reform Act ,Months Ended ,Comprehensive Income ,Redeemable Convertible Preferred ,Common Shareholders ,Annual Report ,Operating Expenses ,Nc ,